Estrella Immunopharma (NASDAQ:ESLA) Stock Rating Lowered by Wall Street Zen

Estrella Immunopharma (NASDAQ:ESLA) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

ESLA has been the topic of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Estrella Immunopharma in a report on Friday, October 31st. D. Boral Capital reiterated a “buy” rating and set a $16.00 price target on shares of Estrella Immunopharma in a research note on Monday, November 3rd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $16.00.

Estrella Immunopharma Stock Performance

NASDAQ:ESLA opened at $0.99 on Friday. The firm’s 50-day moving average is $1.68 and its 200-day moving average is $1.42. The company has a market cap of $37.54 million, a price-to-earnings ratio of -2.92 and a beta of 0.55. Estrella Immunopharma has a 52-week low of $0.73 and a 52-week high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last released its earnings results on Wednesday, November 12th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.06.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.